Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;333:754-755 (7 October), doi:10.1136/bmj.333.7571.754-b
| The first 150 words of the full text of this article appear below. |
EDITORStrang et al say that naloxone is an extraordinarily effective drug, presumably meaning that at adequate doses it always reverses opioid effects.1 (Incidentally, why does one 400 µg ampoule cost the NHS about £5 when it sells for a small fraction of that in other European countries?) Whether naloxone saves lives in opioid overdose when publicly distributed is, as they recognise, still unproved. Intuitively, it seems worth doing (and monitoring), especially if combined with educating relevant peer groups about airways and resuscitation.
However, naloxone is not the only extraordinarily effective opioid antagonist. Apart from the possible advantages in acute opioid overdose of nalmefene, with its longer half-life, almost complete prevention of opioid overdose and of relapse to heroin for many months after detoxification are now demonstrably possible with long-acting naltrexone implants.2 Since the authors note that opioid overdose is particularly dangerous in detoxified, non-tolerant addicts, and since naltrexone
Colin Brewer, research director
Stapleford Centre, London SW1W 9NP cbrewer@doctors.net.uk
Read all Rapid Responses